Using a Clinicopathologic and Gene Expression (CP-GEP) Model to Identify Stage I–II Melanoma Patients at Risk of Disease Relapse

SIMPLE SUMMARY: More than 40% of patients initially diagnosed with ‘low risk’ (stage I–II) melanoma eventually develop melanoma recurrence or die as a result of melanoma. While the current standard of care at diagnosis for these patients is watchful waiting, they may benefit from adjuvant systemic t...

Descripción completa

Detalles Bibliográficos
Autores principales: Mulder, Evalyn E. A. P., Johansson, Iva, Grünhagen, Dirk J., Tempel, Dennie, Rentroia-Pacheco, Barbara, Dwarkasing, Jvalini T., Verver, Daniëlle, Mooyaart, Antien L., van der Veldt, Astrid A. M., Wakkee, Marlies, Nijsten, Tamar E. C., Verhoef, Cornelis, Mattsson, Jan, Ny, Lars, Hollestein, Loes M., Olofsson Bagge, Roger
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9220976/
https://www.ncbi.nlm.nih.gov/pubmed/35740520
http://dx.doi.org/10.3390/cancers14122854

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9220976/
https://www.ncbi.nlm.nih.gov/pubmed/35740520
http://dx.doi.org/10.3390/cancers14122854

Ejemplares similares